Among the report’s top findings:
So-called specialty therapies will dominate spending, with oncology treatments totaling $110 billion, followed by autoimmune drugs. Treatments for viral hepatitis, including Gilead Science Inc.’s hepatitis C drugs Sovaldi and Harvoni along with AbbVie Inc.’s Viekira Pak, will make up $48 billion.
The United States will spend the most on drugs, with 41 percent of the global bill. China will spend $150 billion to $180 billion in 2020, representing a 6 percent to 9 percent compound annual growth rate. The global growth rate is 4 percent to 7 percent.
IMS estimates 225 new treatments will be introduced in the next five years. Of these, drugs for rare diseases and cancers will dominate.
See also: Goldman Sachs: Health care costs are about to start pushing core inflation higher